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ABSTRACT
Background: The preferences and opinions of patients are important when choosing the optimal
inhaler device for asthma management. We compared patient satisfaction of three dry powder inhalers
in patients with moderate to severe asthma.
Methods: We selected a group of patients treated with EasyhalerTM (n = 164) and a second group of
patients treated with TurbuhalerTM (n = 100) or DiskusTM (AccuhalerTM) (n = 64) from the register of an
observational, multicenter study. Data of patients were paired according to age, gender, and asthma
severity. Patient satisfaction with the inhaler type was assessed with the specific ‘Feeling of Satisfaction
with Inhaler’ (FSI-10) questionnaire.
Results: Specific satisfaction with inhaler was statistically significantly higher with EasyhalerTM, as well
as the percentage of patients with high satisfaction with inhaler. (FSI-10 score ≥43). Scores for
EasyhalerTM were also statistically significantly better for individual FSI-10 items such as learning how
to use, inhaler preparation, inhaler use, weight and size, and portability. There were no significant
differences in asthma control (ACT, Mini-AQLQ) and adherence (TAI global score).
Conclusions: Specific satisfaction with inhaler was higher with EasyhalerTM in a homogeneous popula-
tion of patients with moderate to severe asthma. However, the relationship between satisfaction with
the inhaler and adherence and asthma control deserves more investigation.
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When choosing asthma inhaled therapy, taking into account
the preferences and opinions of patients can improve adher-
ence and asthma control [1,2]. Patient satisfaction with inhaler
has been related to more favorable clinical outcomes [3], just
as difficulties using the inhaler have been shown to contribute
to poor adherence [2]. Thus, inhaler choice is considered key
for asthma control [4].
Dry powder inhalers (DPIs) are used in asthma therapy
[2]. However, they present different features that may have
clinical implications [5]. EasyhalerTM (EH) (Orion Corporation,
Finland), is a three-step, light, compact, and user-friendly
DPI. It has advantages over older DPIs [6], including dose
uniformity in different real-world conditions [7]. With regard
to features such as perception of inhalation, size, discreet-
ness, mouthpiece comfort, and dose counter, EH was rated
higher than other inhaler devices by asthma patients [8]. In
an observational, multicenter study, patient satisfaction with
inhaler was higher in asthma patients treated with EH [9].
Here we present a post-hoc analysis of a homogeneous
subpopulation of this study. Our objective was to compare
EH and other DPIs regarding patient satisfaction with inha-
ler and potential clinical differences.
2. Materials and methods
The method used in the ASCONA (Asthma Satisfaction,
CONtrol and Adherence) study has been previously reported
[9]. Briefly, the ASCONA scientific committee selected and
invited the participating physicians. This selection aimed to
achieve an appropriate geographical distribution across
Spain, as well as involving centers providing different levels
of healthcare. Seventy-three investigators (50.7% allergists
and 49.3% pulmonologists) participated in the study. They
selected 800 consecutive patients according to the inclusion
criteria: age ≥ 18 years, physician-confirmed asthma diag-
nosis, moderate to severe asthma according to GINA guide-
lines [2], and in receipt of any kind of asthma medication
with the same inhaler for at least 3 months prior to their
inclusion in the study. This last criterion was intended to
assure that patients were under steady treatment without
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recent changes. Prior and current medications were regis-
tered and analyzed. Patients with disabling comorbidities
and/or cognitive dysfunction were excluded. All patients
signed an informed consent form, no personal data were
recorded, and neither physicians nor patients received any
compensation for their participation.
Physicians and patients completed electronic data collec-
tion forms in a single visit. We recorded sociodemographic
and clinical data, including age at asthma diagnosis and at
therapy onset, current asthma therapy, and asthma severity
and control according to GINA [2]. We also included several
questionnaires and tests. We assessed satisfaction with the
specific Feeling of Satisfaction with Inhaler (FSI-10) ques-
tionnaire [10] and the more general Treatment Satisfaction
Questionnaire for Medication (TSQM) [11]. For adherence,
we used the Test of Adherence to Inhalers (TAI) to assess
the specific adherence to inhalers [12] and the 4-item
Morisky-Green scale for the general adherence to treatment
(where 0 is no adherence and 4 is good adherence) [13]. We
also used the Asthma Control Test (ACT) [14] and the
reduced version of the Asthma Quality of Life
Questionnaire (Mini-AQLQ) [15,16]. All these instruments
have been validated in Spanish [10,12,17–20]. Furthermore,
FSI-10 and TAI have been developed in Spain.
The specific FSI-10 questionnaire assesses the portability
and usability of inhalers regardless of administered drugs.
Patients answer ten questions, each with five options, using
a Likert scale from 5 (very) to 1 (hardly at all). The FSI-10
maximum score is 50 (maximum satisfaction) [10] (see
Supplementary file 1).
In turn, TAI consists of two complementary question-
naires. The 10-item TAI is completed by the patient and
identifies the level of adherence: good (50 points), inter-
mediate (46–49 points), and poor (≤ 45 points). In turn,
the 12-item TAI suggests the pattern of non-compliance. It
includes the 10-item TAI plus two items that are answered
by the physician: knowledge of the dosing regimen by the
patient (item #11) and performance of inhalation techni-
que without critical errors (item #12) [12] (see
Supplementary file 2).
The study was conducted according to the Declaration of
Helsinki. The Clinical Research Ethics Committee of the
Hospital Clinic in Barcelona (Spain) approved its protocol.
The more common DPIs in the ASCONA register were EH,
TurbuhalerTM (TH) (AstraZeneca, Sweden) or DiskusTM
(AccuhalerTM) (DKAH) (GSK, United Kingdom). They also
were the only ones with an adequate number of patients
to perform statistical analyses. In a prior analysis of the
ASCONA registry, study investigators included 739 patients
with moderate or severe asthma treated with EH, TH or
DKAH. The comparison between these three DPIs showed
a significant trend favorable to EH when compared both
versus TH and versus AH individually in specific satisfaction
to inhaler, satisfaction with treatment, quality of life, and
asthma control [21] (see Supplementary file 3), without
significant differences in other variables. However, because
of non-systematic recruitment in the ASCONA registry, DPI
groups were heterogeneous (in size and clinical profile) and
therefore not directly comparable. For instance, percentage
of patients with moderate asthma was higher in the EH
group (p < 0.001). Therefore, we decided to perform a post-
hoc analysis using two randomized paired samples of
patients matched according to age, gender and asthma
severity, and treated with EH or with TH/DKAH. To explore
whether this EH differences were relevant or not, we cre-
ated homogeneous groups using paired matched samples
approach, which will provide enough statistical power by
unifying comparator groups (TH and AH) only under the
assumption that they differ in a similar degree on the EH
results.
2.1. Statistical analysis
Statistical analysis was performed with SPSS version 22.0
(SPSS Inc., Chicago, IL, USA). All statistical tests, tables and
charts considered only the numbers of valid cases.
Categorical variables were described with number of
valid cases and percentage, whereas mean and standard
deviation (SD) were used for continuous variables.
Dichotomous variables were created for each variable of
interest using the median of the scores from the question-
naires and scales (FSI-10, TSQM, TAI and Mini-AQLQ) or
a pre-established cut-off point (ACT [22] and Morisky–
Green scale [13]).
Statistical tests included one-way analysis of variance
(ANOVA) for group comparisons, Mann-Whitney test or
Kruskal–Wallis test for continuous variables, and χ2 test for
categorical variables. Pearson and Spearman correlation
tests were used to assess relationships between scale
scores. Finally, multivariate analyses were performed to
examine factors that influenced the study dependent vari-
able (specific satisfaction with inhaler according to FSI-10).
3. Results
We included a group of patients treated with EH (n = 164)
and a second group of patients treated with TH (n = 100) or
DKAH (n = 64). Data were paired by gender, age, and
asthma severity (Table 1). There were no statistically signifi-
cant differences between groups in the forced expiratory
volume in one second (FEV1) test (p = 0.443); daytime
asthma symptoms more than twice/week (p = 0.664);










mean ± SD p
Socio-demographic and
clinical data
Age (y) 48.9 (16.16) 47.6 (15.9) ns
Gender (female) 104 (63.4) 104 (63.4) 1
Age at asthma diagnosis (y) 32.7 ± 18.6 29.6 ± 18.8 ns
Age at onset of asthma
therapy (y)
34,34 ± 18,18 31,4 ± 18,3 ns
Asthma severity (GINA) 1
Moderate 120 (73.2) 120 (73.2)
Severe 44 (26.8) 44 (26.8)
ns, non-statistically significant; GINA, Global Initiative for Asthma.
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night waking due to asthma (p = 0.861); need for rescue
medication (p = 0.975); and activity limitation due to
asthma (p = 0.823). No prior or current medication affected
satisfaction with inhaler.
Table 2 shows the differences between groups in terms
of patient satisfaction and adherence. Specific satisfaction
with the inhaler (global score of FSI-10) was statistically
significantly higher with EH compared with TH/DKAH
(p < 0.01). With regard to individual FSI-10 items, patients
considered EH to be easier to learn to use (p = 0.025),
easier to prepare for inhalation (p = 0.01), easier to use
(p = 0.012), and easier to carry (p = 0.018). Patients found
EH easier to continue with regular activities (p = 0.038),
and its weight and size were more convenient (p < 0.001).
In addition, = they felt they had used it correctly after
inhalation (p = 0.02). Overall, patients noted greater satis-
faction with the device (p = 0.001). No statistically signifi-
cant difference was found for device cleaning and
maintenance, or for mouthpiece comfort. Moreover, the
percentage of patients with high satisfaction with inhaler
was statistically significantly higher with EH (p = 0.01).
Regarding general satisfaction with therapy (TSQM),
there were no statistically significant differences in global
scores between DPIs. However, patients in EH group
reported that it was easier to take their medication in its
current form (p = 0.018) and to plan when they will use
the medication each time (p = 0.004). Patients using EH
also found it more convenient to take the medication as
instructed (p = 0.042). Furthermore, all items of adverse
event subscale showed a trend to be lower for EH group,
but without statistical significance; this result is based on
questionnaire answers, not on patient-reported adverse
events of administered drugs. Moreover, convenience
was statistically significantly higher in EH group
(p < 0.01). In addition, the percentage of patients with
high satisfaction with treatment was statistically signifi-
cantly higher in the EH group (p = 0.027).
In respect of specific adherence to inhaler (TAI), there was
no statistically significant difference in TAI global scores
between groups. Nevertheless, mean scores of erratic and
unwitting non-adherence patterns were higher in the EH
group (p < 0.05 for both patterns), reflecting that these non-
adherence patterns were less frequent with EH. There was no
statistically significant difference between groups for general
adherence in global scores of the Morisky–Green scale.
With regard to asthma control, there was no statistically
significant difference in ACT global score or in the percentage
of patients with controlled asthma (ACT score ≥ 20). Finally,
there was no statistically significant difference in health-
related quality of life (Mini-AQLQ).
We performed a logistic regression analysis with specific
satisfaction with inhaler (FSI-10) as a dependent variable
(Figure 1). The most important factor leading to high satisfac-
tion was the use of EH (odds ratio [OR] 1.705; 95% CI
1.056–2.755). Moreover, male gender slightly inclined towards
high satisfaction with inhaler (OR 1.245; 95% CI 0.756–2.051).
Conversely, factors that led to low satisfaction with inhaler
were severe asthma (OR 1.186; 95% CI 0.663–2.120) and non-
controlled asthma (OR 0.390; 95% CI 0.236 −0.643).
4. Discussion
In our real-world study, patient satisfaction with inhaler was
higher with EH than with TH/DKAH. Among other features,
ease of use, convenient weight and size, and ease of portabil-
ity contributed to higher satisfaction with EH. These results
confirm the findings in the whole ASCONA population, where
patient satisfaction was also higher with EH than with TH or
DKAH [9]. Moreover, although the aim of our study was not to
prove the clinical relevance of differences in FSI-10 score,
results of ASCONA main analysis [9] showed that these differ-
ences are clinically relevant.
The preference for EH has been found in other studies in
patients with asthma. Ahonen et al. [23] performed a meta-
analysis of nine clinical trials (n = 802) of EH and metered-
dose inhalers (MDIs) with and without a spacer, TH, and
DiskhalerTM in patients with asthma. Ease of use was statis-
tically significantly better for EH vs. the pooled data
(p < 0.001) and for almost all individual studies. Inhalation
through the device was also easier with EH, as was learning
how to use it. Patients preferred EH to the MDI and spacer
(p < 0.001) and to TH (p < 0.01) [23]. Preference of patients
for EH has also been shown in other randomized clinical
trials in patients with asthma. Jäger et al. [24] compared EH
and TH; almost 59% of patients preferred EH and scores of
device acceptability were higher for EH (p = 0.001).
Similarly, in a study by Tukiainen et al. [25] again 59% of
patients preferred EH vs. TH. Moreover, overall acceptability
was higher for EH (p < 0.0001). In a study by Giner et al. [8],
nine aspects of the inhalers were rated from 0 to 10 for
each device. The overall score was higher for EH vs. TH
(p = 0.015) and vs. DKAH (p = 0.003). When patients were
asked to rank the inhalers in order of preference, EH was











mean ± SD p
Specific satisfaction with inhaler (FSI-10)
FSI-10 score 43.8 ± 7.1 41.3 ± 7.6 < 0.01
High satisfaction (score ≥ 43) 92 (62.4) 68 (43) 0.01
General satisfaction with medication (TSQM)
Effectiveness 71.4 ± 20.6 70.9 ± 18.4 ns
Adverse events 97.1 ± 9.7 94.1 ± 14.3 < 0.05
Convenience 79.7 ± 14.2 75.75 ± 16.1 < 0.01
Global satisfaction 74.6 ± 16.1 72.3 ± 17.7 ns
High global satisfaction (score ≥ 75) 102 (63.4) 84 (51.2) < 0.05
Adherence
TAI
Score 47.1 ± 4.4 46.4 ± 5.1 ns
Good adherence (score ≥ 50) 64 (40.8) 59 (37.1) ns
Non-adherence pattern
Erratic 23.1 ± 2.7 22.4 ± 3.4 < 0.05
Deliberate 24.1 ± 2.2 24.24 ± 2.2 ns
Unwitting 3.9 ± 0.4 3.8 ± 0.4 < 0.05
Morisky-Green scale
Score 3.1 ± 1.1 2.9 ± 1.1 ns
Good adherence (score = 4) 75 (45.1) 59 (36.0) ns
ns, non-statistically significant; FSI-10, Feeling of Satisfaction with Inhaler ques-
tionnaire; TSQM, Treatment Satisfaction Questionnaire for Medication; TAI,
Test of the Adherence to Inhalers.
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placed first by 53% of patients, TH by 27% and DKAH by
20%. In two real-world multicenter studies by Gálffy et al.
[26], patients considered that EH was easy to learn and use,
and 95% were satisfied or very satisfied with this inhaler.
Erratic and unwitting non-adherence patterns were less
frequent in patients using EH. With respect to erratic non-
adherence, we could not find a direct relationship
between forgetting to take the dose and the different
inhaler devices. Regarding the lower unwitting non-
adherence with EH, we suggest that it was due to its
ease of use, with only three steps and therefore fewer
technical errors. There were no statistically significant dif-
ferences between groups in terms of global adherence
scores. Similarly, asthma control was comparable in both
groups. A relationship between satisfaction and adherence
has been found in other studies [3,27], but these did not
compare different inhalers. In the main analysis of
ASCONA, high patient satisfaction with inhaler was related
to adherence and asthma control [9]. However, because of
the sample size in our subanalysis, the difference in satis-
faction was insufficient to be reflected in adherence and
asthma control.
The main strengths of our study are the population
homogeneity and the use of validated and specific scales
and questionnaires. Regarding potential limitations, adher-
ence was self-reported except for items 11 and 12 of TAI.
However, these two physician-reported items define the
unwitting non-adherence pattern. Another potential lim-
itation could be that different drug combinations may
affect results.
5. Conclusions
Physicians should keep in mind patient satisfaction with
asthma therapy, and especially specific satisfaction with
the inhaler. In this setting, EH is well valued by patients.
In our homogeneous population of patients with moder-
ate to severe asthma, specific satisfaction with the inhaler
was higher with EH.
However, the relationship between satisfaction with the
inhaler and adherence and asthma control deserves more
investigation.
Key issues
● Physicians should keep in mind patient satisfaction with
asthma therapy, and especially specific satisfaction with
the inhaler.
● Dry powder inhalers (DPIs) present different features
that may have clinical implications.
● EasyhalerTM has been shown to have advantages over
older DPIs in prior studies.
● In a homogeneous population of patients with moder-
ate to severe asthma, specific satisfaction with inhaler
(measured with the FSI-10 questionnaire) was statisti-
cally significantly higher with EasyhalerTM (43.8 ± 7.1)
compared with TurbuhalerTM or DiskusTM (AccuhalerTM)
(41.3 ± 7.6) (p < 0.01).
● Moreover, high satisfaction with inhaler was statistically
significantly higher with EasyhalerTM (62.4% of patients)
than with TurbuhalerTM or DiskusTM (AccuhalerTM) (43%
of patients) (p = 0.01).
Figure 1. Binary logistic regression analysis using specific satisfaction with inhaler (FSI-10) as dependent variable. Use of EasyhalerTM led to high specific satisfaction
with inhaler.
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● This preference for EH has been found in other studies in
patients with asthma.
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